Dong-a St Co., Ltd.

Dong-a Pharmaceutical Co., Ltd

Yu Na Chae

Chang Yell Shin

Eun Kyoung Yang

Mi-Kyung Kim

Jae Young Lee

Bo Ram Lee

Tae Hyoung Kim

Chi Young Ahn

Mi Kyung Kim

Moohi Yoo

Woo Young Kwak

Hyo Ju Lee

Heung Jae Kim

Soon Hoe Kim

Yoon Jung Kim

Jae Sung Yang

Jong Pil Min

Tae Hyun Yoon

Moon-Ho Son

Hansu Park

Song-Hyen Choi

Moon Ho Son

So Mi Kang

Il Hoon Jung

Ye Hwang Cheong

Gye Rim Baek

Seung Ho Lee

Gook Jun Ahn

The present invention pertains to a pharmaceutical composition for preventing or treating non-alcoholic fatty liver disease, the composition containing G protein coupled receptor 119 (GPR119) ligand as an active ingredient. The pharmaceutical composition according to the present invention exhibits the excellent effects of improving lipid metabolism, reducing fat accumulation in liver tissues, and preventing histological damage caused by inflammation and fibrosis in liver tissues, and can thus be useful in preventing or treating non-alcoholic fatty liver disease.

Pharmaceutical composition for preventing or treating nonalcoholic fatty liver disease, containing GPR119 ligand as active ingredient

The present invention relates to a substituted piperidines represented by following Chemical Formula 1, which have a GPR119 agonistic activity, a method for preparing the same, and a pharmaceutical composition including the same: wherein A, B, and X are defined therein.

Substituted piperidines having GPR119 agonistic activity

The present invention relates to a pharmaceutical composition for the prevention and treatment of diabetes or obesity comprising as active ingredients a compound which inhibits the activity of dipeptidyl peptidase-IV (DPP-IV), a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, and one or more other antidiabetic or antiobesity agents. The pharmaceutical composition exhibits excellent glucose tolerance and may be useful in the prevention and treatment of diabetes, obesity, and the like by effectively inhibiting blood glucose levels and reducing fat mass.

Pharmaceutical composition for prevention and treatment of diabetes or obesity comprising a compound that inhibits activity of dipeptidyl peptidase-IV, and other antidiabetic or antiobesity agents as active ingredients

Growing community of inventors

Gyeonggi-do, South Korea

Yu Na Chae